Effect of skin pretreatment with fatty acids on percutaneous absorption and skin retention of piroxicam after its topical application

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 50, Issue 2, 2000, Pages 245-250

  Santoyo, S ^a   Ygartua, P ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Fatty acids; Penetration enhancers; Percutaneous absorption; Piroxicam; Skin pretreatment

Indexed keywords

CARBOMER; DRUG VEHICLE; FATTY ACID; LINOLEIC ACID; LINOLENIC ACID; PIROXICAM;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRUG TRANSPORT; NONHUMAN; RAT; SKIN ABSORPTION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FATTY ACIDS; GELS; MALE; PERMEABILITY; PIROXICAM; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION;

EID: 0033840314     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(00)00097-7     Document Type: Article

References (28)

1. B.W. Barry, Lipid-protein-partitioning theory of skin penetration enhancement, J. Control. Release. 15 (1991) 237-248.
2. E.J. Baker, J. Hadgraft, In vitro percutaneous absorption of arildone, a highly lipophilic drug, and the apparent no-effect of the penetration enhancer azone in excised human skin, Pharm. Res. 12 (1995) 993-997.
3. H. Tanojo, J.A. Bouwstra, H.E. Junginger, H.E. Boddé, In vitro human skin barrier modulation by fatty acids: skin permeation and thermal analysis studies, Pharm. Res. 14 (1997) 42-49.
4. S.Y. Oh, S.Y. Jeong, T.G. Park, J.H. Lee, Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer, J. Control. Release 51 (1998) 161-168.
5. B.M. Elyan, M.B. Sidhom, F.M. Plakogiannis, Evaluation of the different fatty acids on the percutaneous absorption of metaproterenol sulfate, J. Pharm. Sci. 85 (1996) 101-105.
6. Y. Takeuchi, Y. Yamaoka, S. Fukushima, K. Miyawaki, K. Taguchi, H. Yasuka, S. Kishimoto, M. Suzuki, Skin penetration enhancing action of cis-unsaturated fatty acids with ω-9 and ω-12 chain lengths, Biol. Pharm. Bull. 21 (1998) 484-491.
7. K.S. Bhatia, J. Singh, Synergistic effect of iontophoresis and a series of fatty acids on LHRH permeability through porcine skin, J. Pharm. Sci. 87 (1998) 462-469.
8. K. Taguchi, S. Fukushima, Y. Yamaoka, Y. Takeuchi, M. Suzuki, Enhancement of propylene glycol distribution in the skin by high purity cis-unsaturated fatty acids with different alkyl chain lengths having different double bond position, Biol. Pharm. Bull. 22 (1999) 407-411.
9. G.M. Golden, J.E. McKie, R.O. Potts, Role of stratum corneum lipid fluidity in transdermal drug flux, J. Pharm. Sci. 76 (1987) 25-28.
10. B. Ongpipattanakul, R.R. Burnette, R.O. Potts, M.L. Francoeur, Evidence that oleic acid exists in a separate phase within SC lipids, Pharm. Res. 8 (1991) 350-354.
11. M. Walker, J. Hadgraft, Oleic acid - a membrane "fluidiser" or fluid within the membrane? Int. J. Pharm. 71 (1991) R1-R3.
12. P. Schiantarelli, S. Cadel, Piroxicam pharmacologic activity and gastrointestinal damage by oral and rectal route, Arzneim.-Forsch. Drug Res. 31 (1981) 87-92.
13. P. Schiantarelli, S. Cadel, D. Acerbi, L. Pavesi, Anti-inflammatory activity and bioavailability of percutaneous piroxicam, Arzneim.-Forsch. Drug Res. 32 (1982) 230-235.
14. Y.H. Tsai, L.R. Hsu, S.I. Natio, Percutaneous absorption of piroxicam from ointment bases in rabbits, Int. J. Pharm. 24 (1985) 61-78.
15. A. Babar, U.D. Solanki, A.J. Cutie, F. Plakogiannis, Piroxicam release from dermatological bases: in vitro studies using cellulose membrane and hairless mouse skin, Drug Dev. Ind. Pharm. 16 (1990) 523-540.
16. R. Marks, P. Dykes, Plasma and cutaneous levels after topical application of piroxicam gel: a study in healthy volunteers, Skin Pharmacol. 7 (1994) 340-344.
17. L.R. Hsu, Y.B. Huang, P.C. Wu, Y.H. Tsai, Percutaneous absorption of piroxicam from FAPG base through rat skin: effects of fatty acids added to FAPG base, Int. J. Pharm. 106 (1994) 1-4.
18. S. Santoyo, A. Arellano, P. Ygartua, C. Martín, Penetration enhancer effects on the in vitro percutaneous absorption of piroxicam through rat skin, Int. J. Pharm. 117 (1995) 219-224.
19. H. Okuyama, Y. Ikeda, S. Kasai, K. Imamori, K. Takayama, T. Nagai, Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm, Int. J. Pharm. 186 (1999) 141-148.
20. S.C. Shin, C.W. Cho, H.K. Choi, Permeation of piroxicam from the poloxamer gels, Drug Dev. Ind. Pharm. 25 (1999) 273-278.
21. B.J. Aungst, Fatty acids as skin penetration enhancers, in: E.W. Smith, H.I. Maibach (Eds.), Percutaneous Penetration Enhancers, CRC Press, Boca Raton, FL, 1995, pp. 277-289.
22. B.M. Elyan, M.B. Sidhom, P.M. Plakogiannis, Evaluation of the effect of different fatty acids on the percutaneous absorption of metaproterenol sulfate, J. Pharm. Sci. 85 (1996) 101-105.
23. Y. Komata, A. Kaneko, T. Fujie, Accumulation of lauric acid in skin as an enhancer for the percutaneous absorption of thiamine disulfide, Bio. Pharm. Bull. 18 (1995) 791-793.
24. C.K. Lee, T. Uchida, E. Noguchi, N.-S. Kim, S. Goto, Skin permeation enhancement of tegafur by ethanol/panasate 800 vehicle and combined effect of fatty acids and fatty alcohols, J. Pharm. Sci. 82 (1993) 1155-1159.
25. Y. Takeuchi, H. Yasukawa, Y. Yamaoka, K. Taguchi, S. Fukushima, Y. Shimonaka, H. Nishinaga, Y. Morimoto, Behavior of propylene glycol (PG) in dermis after treatment of rat intact skin surface with fatty acids, fatty amines or azone dissolved in PG, Biol. Pharm. Bull. 18 (1995) 304-309.
26. P.G. Green, R.G. Guy, J. Hadgraft, In vitro and in vivo enhancement of skin permeation with oleic and lauric acids, Int. J. Pharm. 48 (1988) 103-111.
27. T.M. Suhonen, J.A. Bruwstra, A. Urtti, Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations, J. Control. Release 59 (1999) 149-161.
28. P. Singh, M.S. Roberts, Skin permeability and local tissue concentration of nonsteroidal anti-inflammatory drugs after topical application, J. Pharmacol. Exp. Ther. 268 (1994) 144-151.